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Human airwayDevelopment of physiologically relevant test methods to analyse potential irritant effects to the respira-
tory tract caused by e-cigarette aerosols is required. This paper reports the method development and
optimisation of an acute in vitro MTT cytotoxicity assay using human 3D reconstructed airway tissues
and an aerosol exposure system. The EpiAirway™ tissue is a highly differentiated in vitro human airway
culture derived from primary human tracheal/bronchial epithelial cells grown at the air–liquid interface,
which can be exposed to aerosols generated by the VITROCELL smoking robot. Method development was
supported by understanding the compatibility of these tissues within the VITROCELL system, in terms of
airﬂow (L/min), vacuum rate (mL/min) and exposure time. Dosimetry tools (QCM) were used to measure
deposited mass, to conﬁrm the provision of e-cigarette aerosol to the tissues. EpiAirway™ tissues were
exposed to cigarette smoke and aerosol generated from two commercial e-cigarettes for up to 6 h.
Cigarette smoke reduced cell viability in a time dependent manner to 12% at 6 h. E-cigarette aerosol
showed no such decrease in cell viability and displayed similar results to that of the untreated air con-
trols. Applicability of the EpiAirway™ model and exposure system was demonstrated, showing little
cytotoxicity from e-cigarette aerosol and different aerosol formulations when compared directly with ref-
erence cigarette smoke, over the same exposure time.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
E-cigarettes1 are increasing in popularity throughout the world.
Whilst the devices themselves are subject to some regulation, e.g.
CE marking, there are no standard regulations relating to character-
isation of the emissions and their impact on biological systems.
E-cigarettes appear to be much safer than cigarettes, but further
studies are required to fully assess their safety for long-term use
(Caponnetto et al., 2012). Concerns regarding the possible adverse
effects have been raised (Etter, 2010; McQueen et al., 2011; Chen,
2013; Goniewicz et al., 2013). These effects include irritation of
the mouth and throat that may diminish over time, indicating a tran-
sient effect (Polosa et al., 2011). So far only limited in vitro research
into the toxicity of inhaled e-cigarette aerosol, which can contain
nicotine, humectants (e.g. glycerol or propylene glycol), ﬂavouring
ingredients (e.g. menthol) and thermal degradation products, hasbeen done. Desk-based risk assessment of the ingredients contained
within e-liquids has highlighted a speciﬁc requirement to under-
stand the potential for irritant effects to the respiratory tract caused
by e-cigarette aerosols.
A number of in vitro tests, largely been based on cytotoxicity
responses in cell culture systems have been developed to predict
irritation potential of chemicals (Vinardell and Mitjans, 2006;
McNamee et al., 2009; Katoh et al., 2013; Kolle et al., 2013;
Pfannenbecker et al., 2013). Increasingly, emphasis is being placed
on the introduction of more-physiologically relevant in vitro toxic-
ity test systems, which presents particular challenges when mim-
icking inhalation exposures. Whilst there are as yet are no
regulatory deﬁned procedures, exposure systems such as the
VITROCELL smoking robot (VITROCELL Systems GmbH,
Waldkirch, Germany) and its associated exposure apparatus are
widely referenced in the literature for use with cigarette smoke
(Iskandar et al., 2013; Schlage et al., 2014), nanoparticles
(Fröhlich et al., 2013; Klein et al., 2013) and pollutant/airborne
chemicals (Anderson et al., 2010; Gminski et al., 2010). This expo-
sure system can deliver intact aerosol to cell culture systems and is
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respiratory tract exposure (Thorne and Adamson, 2013; Panas
et al., 2014). Such exposure systems would ideally be coupled to
more sophisticated human 3D2 reconstructed respiratory tissue to
provide the optimum representation of human exposure (Mathis
et al., 2013; Talikka et al., 2014).
No speciﬁc studies have yet been reported for irritancy of
e-cigarette aerosol, however, a variety of published work has been
conducted with cytotoxicity as an endpoint. E-liquids have some
cytotoxic effects, as measured with the MTT assay in mouse neural
stem cells and human primary ﬁbroblasts (Bahl et al., 2012). Some
cytotoxic effects from e-cigarette vapours have also been reported
inmyocardial cells (Farsalinos et al., 2013), A549 lungepithelial cells
(Cervellati et al., 2014) and BALB/c 3T3mouse ﬁbroblasts (Romagna
et al., 2013), although allwere signiﬁcantly less than those produced
by cigarette smoke. The reported cytotoxic effects have been related
to the ﬂavourings rather than the base ingredients (including nico-
tine) (Bahl et al., 2012; Farsalinos et al., 2013; Behar et al., 2014).
The need for development of physiological relevant testmethods
to analyse potential irritant effects to the respiratory tract caused by
e-cigarette aerosols is clear. This study reports the development of a
protocol to evaluate the acute irritant potential of e-cigarette aero-
sols (and formulations) and cigarette smoke exposed at the air–liq-
uid interface, using QCM technology to support exposure scenarios
and a commercially available human 3D airway tissue model,
EpiAirway™ (MatTek Corporation, Ashland, MA, USA). Parallel
learnings were taken from the evolution of the OECD test guideline
439 (OECD, 2013) for in vitro skin irritation, using reconstructed
human epidermis, in which the endpoint is cell viability (measured
through reduction of MTT) using a prediction model based on 50%
viability or less of that for concomitantly, run negative controls.
The capability of the EpiAirway™ tissues to distinguish between
known respiratory tract irritants and non-irritants was conﬁrmed.
Test articles were selected from the proﬁciency chemicals listed
within the OECD test guideline 439 for in vitro skin irritation in
reconstructed human epidermis (OECD, 2013) and also classiﬁed
as respiratory tract irritants and non-irritants. In addition, the respi-
ratory irritant butylmethacrylatewas included,whichwas used as a
skin irritant during the European Centre for the Validation of
Alternative Methods validation studies (Griesinger et al., 2009).
This study further investigated exposure parameters that are speci-
ﬁc to e-cigarette aerosol testing in vitro using the VC 10 exposure
system and demonstrates the use of QCM dose tools to quantify
delivery of the e-cigarette aerosol to the surface of the cell cultures.
Finally, the results demonstrate that e-cigarette aerosol and aerosol
formulations tested in this study are signiﬁcantly less irritant when
compared to cigarette smoke generated from a 3R4F reference pro-
duct over an equivalent 6 h exposure timeframe.2. Materials and methods
2.1. Chemicals and reagents
All chemicals and reagents were obtained from Sigma Aldrich
(St Louis, MO, USA) unless otherwise stated. All tissue-culture
media, assay reagents, and extractants were supplied by MatTek
Corporation (Ashland, MA, USA).3 Phosphate buffered saline.2.2. Organotypic culture of tracheobronchial epithelial cells
EpiAirway™tissuesare3D, fullydifferentiated invitroreconstructs
of primary human tracheobronchial epithelium. Cultures are pro-
duced through adaptation of previously established methods (Adler2 Three-dimensional.
4 NJOY King Traditional Bold.
5 NJOY King Menthol Gold.et al., 1987; Kaartinen et al., 1993). Brieﬂy, primary tracheobronchial
epithelial cells were seeded on collagen-coated Transwell inserts
(Corning,NY,USA)andgrownsubmerged toobtaina conﬂuentmono-
layer. Thismonolayerwas lifted to the air–liquid interface and grown
in differentiation media until fully differentiated. Mature cultures
expressmucusproducinggoblet cells, ciliated cellswith activelybeat-
ing cilia, basal cells, and club cells (Clara). The donor of primary cells
used in these experiments was a 23-year old Caucasian male with
no smoking history and no history of respiratory disease.
Throughout the experiments, EpiAirway™ tissues were cultured in
maintenance media (AIR-100) according to manufacturer’s recom-
mendations. EpiAirway™ tissues were used in two insert formats,
AIR-100 (surface area 0.6 cm2) for initial apical testing and
AIR-100-PC12 (surface area 1.12 cm2), in 12 mm Transwells, for
aerosol exposures and experimental controls. Three replicate tissues
were used for each test item, unless otherwise stated.
2.3. Apical exposure to liquid test articles
The apical surface of EpiAirway™ tissues (AIR-100) were rinsed
twice with 400 lL PBS3 to remove accumulated mucus. Tissues were
transferred to 6-well culture plates with 1.0 mL of maintenance
media per well. Butyl methacrylate (97-88-1), heptanal (111-71-7),
heptyl butyrate (5870-93-9), and methyl stearate (112-61-8) were
diluted to the indicated concentrations in olive oil (8001-25-0)
(Persson et al., 1991; Erjefalt and Persson, 1992; Farraj et al., 2006;
Sun et al., 2006). For each experiment, tissues were treated in tripli-
cate with 100 lL of each test article, vehicle control (olive oil), or
0.1% Triton X-100 (9002-93-1) as the positive control on the apical
surface, for 3 h in a 37 C, 5% CO2 incubator. Untreated (incubator)
controls were also included in each experiment. Following exposure,
the apical surface was rinsed three times with 400 lL PBS, and the
MTT assay for tissue viability was performed (Sauer et al., 2013).
2.4. Cigarettes and Electronic cigarettes
Reference 3R4F cigarettes were obtained from the University of
Kentucky (Lexington, KY, USA). Cigarettes were conditioned in a
humidity chamber with approximately 58% humidity at room tem-
perature (20–23 C) for at least 48 h prior to being smoked. Two
commercially available e-cigarettes were obtained from NJOY
(Scottsdale, AZ, USA) between October 2013 and April 2014: NJOY
Bold4 and NJOY Menthol5 were labelled on the packaging, respec-
tively, as containing 4.5% and 3.0% nicotine by volume, as speciﬁed
by the manufacterer. No analysis was carried out to conﬁrm nicotine
levels.
2.5. Aerosol generation and exposure
A VITROCELLVC 01 Smoking Robot (VC1/110613) and a 12/6 CF
stainless-steel exposuremodule (VITROCELL SystemsGmbH)were
used to expose EpiAirway™ tissues to cigarette smoke, e-cigarette
aerosol, or diluting air. Brieﬂy, the VC 01 is a single port, single syr-
inge smoking robot combined with a VITROCELL dilution system
andexposuremodule. The dilutionprinciple of theVC 01 is the same
as other VITROCELL systems, such as the VC 10 (Adamson et al.,
2014), where diluting airﬂow is added perpendicular to the gener-
ated aerosol to create a turbulent homogenous mixture of diluted
aerosol travelling along the dilution system through to exhaust.
Diluted aerosol is sub-sampled from the dilution system into the
exposure module via negative pressure, applied via a vacuum
(Fig. 1).
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(35 mL puffs drawn over 2 s with 1 min intervals) in accordance with
the standard ISO 3308:2012, and using an 8 s exhaust and a
bell-shaped smoking curve. Cigarettes were smoked to eight puffs/cig.
E-cigaretteswere puffed for 30 min, equating to 60 puffs at an indepen-
dent intensepufﬁng regime,deﬁnedasa80 mLpuffdrawnover3 swith
30 s intervals, and using a square-wave pufﬁng proﬁle, to actuate the
electronic device. Given that there is currently no standard pufﬁng
regime for the assessment of e-cigarettes, the independent e-cigarette
pufﬁng regimeselecteddelivered a largerpuff volume,more frequently,
andovera longeractivation timethan traditional, standardisedsmoking
regimes. In essence, the independent pufﬁng regime selected for use in
this study potentially provides a dose to the cell cultures that exceeds
that generated by either ISO or Health Canada Intense (Baker, 2002)
machine smoking regimes (Table 1).
For all experiments, the diluting airﬂow was set to 1.0 L/min
with a 25.0 mL/min vacuum rate, unless otherwise stated.
Airﬂows were maintained and controlled by mass ﬂow controllers
(Analyt-MTC GmbH, Mülheim, Germany). The diluting airﬂow was
set to 1.0 L/min for the duration of the study to ensure a suitable
turbulence within the mixing bar to produce a homogenous test
article (Adamson et al., 2013). Diluting airﬂow rates were not
assessed within this study, due to the exposure aerosol generation
limitations of the VC 01 smoke exposure system. Rather, exposure
time was used to modify exposure conditions as previously
demonstrated by Aufderheide et al., 2003.
Vacuum rates were maintained for the duration of the experi-
ment by vacuum valve blocks (VITROCELL Systems GmbH) having
been conﬁrmed by mass ﬂow meters (Analyt-MTC GmbH).
Cigarette and e-cigarette doses were modiﬁed by sequentially
increasing cigarette or e-cigarette numbers to take exposure up
to 6 h rather than via diluting airﬂow. Cigarette smoke and
e-cigarette aerosol were diluted with medical-grade air comprising
76.5–80.5% nitrogen and 19.5–23.5% oxygen.
The apical surfaces of tissues (AIR-100-PC12) were rinsed three
times with 500 lL PBS and transferred to the exposuremodule con-
taining 1.5 mL AIR-100 maintenance media per well. During each
exposure, three tissue samples were exposed to smoke or aerosol
and three were exposed to diluting air only for the indicated time.
During the characterisation of the exposure parameters, six tissue
samples were exposed to diluting air under two different vacuum
rates (three samples per experiment). Untreated (incubator) control
tissue samples were included in each experiment along with posi-
tive control samples treated apically with 200 lL Triton X-100
(0.05% for 6 h), maintained in a 37 C, 5% CO2 incubator. Control tis-
sues were subject to the same procedures as test tissues and a min-
imum of three samples were included in each experiment. After
exposure, the apical surfaces of all tissue samples were rinsed and
processed for analysis as described below.2.6. Measurement of deposited mass
QCM were installed into a 6/4 CF stainless-steel exposure mod-
ule (VITROCELL Systems GmbH) combined with a VITROCELL VC
10 Smoking Robot (VC10/141209), and were used in an ofﬂine
capacity to support exposure scenarios. QCM technology has been
previously described and utilised in combination with the
VITROCELL set-up (Thorne et al., 2013; Adamson et al., 2014;
Kilford et al., 2014). This study conﬁrmed and strengthened the
applicability of QCM technology to act as a qualitative and quanti-
tative tool to support in vitro exposure scenarios/experimentation.
Brieﬂy, a QCM unit consists of 5 MHz AT-cut quartz crystals held
between two Au/Cr polished electrodes, roughly 2.5 cm in6 International Organisation for Standardization.diameter. They have previously been used for the assessment of
atmospheric nanoparticles, ultraﬁne particles derived from diesel
exhaust, cigarette smoke, and as biosensors for antibody recogni-
tion (Desantes et al., 2006; Mülhopt et al., 2009; Yao et al., 2010;
Adamson et al., 2013). The associated computer software converts
the change in crystal oscillating frequency that occurs due to depo-
sition on the crystal surface into mass per surface area (ng/cm2).
QCMs read at a resolution of 10 ng/cm2 per sec, and mass readings
are recorded every 2 s.
2.7. MTT assay for tissue viability
Tissue viability was measured by reduction of the tetrazolium
saltMethyl Thiazoyl Tetrazolium (MTT) immediately post exposure,
which allows for the measurement and assessment of direct acting
compounds. Although not assessed here, a recovery period could
be employed in this model to assess indirect acting compounds. In
brief, the MTT reagent (MTT-100) was prepared by reconstituting
2 mL of MTT concentrate in 8 mL of MTT diluent. Apical surfaces of
EpiAirway™ tissues were rinsed with PBS following exposures.
AIR-100 tissue samples were transferred to 24-well culture plates
containing 300 lL MTT reagent per well and AIR-100-PC12 tissues
were transferred to 12-well culture plates containing 750 lL MTT
reagentperwell. Tissueswere incubated in a 37 C, 5%CO2 incubator
for 90 min,with the exception of the AIR-100 tissues thatwere incu-
bated with MTT reagent for 3 h. Following incubation, AIR-100 tis-
sues were submerged in 2.0 mL MTT extractant and AIR-100-PC12
tissues in 4.0 mL extractant, in which all tissue samples were main-
tained overnight at room temperature. The following day, 200 lL
extractant from each tissue was transferred to a clear 96-well plate
and absorbance was read at 570 nm with background subtraction
at 650 nm.Viability for each tissue replicate exposed to anapical test
substance, cigarette smoke, e-cigarette aerosol, or diluting air were
calculated with the OD7 relative to the negative control (vehicle,
untreated incubator controls, or no vacuum controls), according to
the following equation: relative viability = [ODtest tissue/mean
ODnegative control]  100. Test items were considered to be an irritant
if a reduction of P50% tissue viability relative to negative controls
was demonstrated. Control EpiAirway™ tissues treated with Triton
X-100 were included to conﬁrm functionality of the assay.
2.8. Measurement of transepithelial electrical resistance
Integrity of the airway epithelium tight junctions was measured
by TEER8 conducted according to the MatTek Corporation’s standard
protocol, before and after aerosol treatments and control exposures,
with an EVOM2 voltohmmeter with a 12 mm EndOhm culture cup
(World Precision Instruments, Sarasota, FL, USA). The EndOhm cup
was equilibrated with 4 mL PBS, according to manufacturer’s recom-
mendations. Before TEER measurement, the apical surface of the tis-
sues was rinsed three times with PBS. A fresh aliquot of 500 lL PBS
was added to the tissue insert and remained on the apical surface for
measurement. The volume of PBS within the EndOhm cup was
reduced to 2.5 mL and the tissue insert placed within. TEER was
recorded once the reading on the EVOM2 stabilized. The background
resistance of PBS only was recorded and subtracted from all mea-
surements. The raw resistance value (after background subtraction)
was multiplied by 1.12 (surface area of AIR-100-PC12) resulting in
ﬁnal values with units of X/cm2. The results of TEER following expo-
sure are presented as percentages of the pre-exposure values.
2.9. Data presentation and statistics7 Optical density.
8 Transepithelial electrical resistance.
Fig. 1. Schematic representation of the VITROCELL VC 01 Smoking Robot, mammalian 12/6 CF stainless-steel exposure module, and EpiAirway™ tissue model. (A) VC 01
single port smoking robot, enclosed in a ventilation hood with a piston/syringe that draws and delivers smoke or aerosol to the dilution bar. (B) Dilution bar, where smoke or
aerosol is diluted, mixed, and delivered to the exposure module. Diluted smoke/aerosol within the dilution bar transits to exhaust. (C) 12/6 CF stainless-steel exposure
module, where EpiAirway™ inserts are housed during exposure. (D.I) Culture insert on which EpiAirway™ tissue culture is supported at the air–liquid interface with smoke/
aerosol distributing ‘‘trumpet’’ sitting 2 mm above the surface of the tissue. (D.II) EpiAirway™ human airway epithelium. (D.III) Fresh culture media (AIR-100 maintenance
media) basally feeding human airway epithelium. Transmission electron micrograph (magniﬁcation  20,000) showing (E.I) cilia and (E.II) tight junctions. Haematoxylin and
eosin stained cross-sections (magniﬁcation  360) of (E.III) pseudostratiﬁed mucociliary morphology of EpiAirway™ tissue and (F) excised human bronchial epithelium for
comparison.
Table 1
Machine smoking regimes.
Puff volume
(mL)
Puff
duration (s)
Puff
frequency (s)
Puff
proﬁle
ISO6 35 2 60 Bell shape
Health Canada
Intense
55 2 30 Bell shape
E-cigarette
intensea
80 3 30 Square
waveb
a Designed for this study to generate more e-cigarette aerosol than traditional
cigarette machine smoking regimes.
b A square-wave proﬁle was used to actuate e-cigarettes for longer than bell-
shaped proﬁles.
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with GraphPad Prism 6. IC509 and ET5010 values were calculated
with GraphPad Prism 6 and a four-parameter-curve ﬁt. All statistical
analyses were conducted with unpaired t-tests.
3. Results
3.1. Tissue functionality from an apical perspective
EpiAirway™ tissues were initially assessed using a direct apical
exposure. Cell viability after 3 h incubation, compared with
vehicle-treated controls (olive oil), indicated that heptyl butyrate
and methyl stearate were non-irritants (reductions up to 99%9 Concentration to inhibit cell viability to 50%.
10 Exposure time to reduce cell viability to 50%.and 88%, respectively) when tested at concentrations of up to
850 mg/mL. The two known respiratory irritants, butyl methacry-
late and heptanal showed reduced cell viability in a
dose-dependent manner of P20% relative to vehicle control
(Fig. 2). The IC50 value was calculated as 117.2 mg/mL (R2 = 0.97)
for heptanal and 313.8 mg/mL (R2 = 0.80) for butyl methacrylate.
This, irritants heptyl butyrate, methyl stearate, butyl methacrylate
and heptanal responded as predicted in this airway model using an
apical exposure.
3.2. Characterisation of exposure parameters
The air control showed that the diluting air does not affect the
viability of the tissues for up to 6 h (102%), and that Triton X-100 is
an effective positive control by reducing cell viability by more than
50% (Fig. 3A). The effects of vacuum rate and exposure time were
assessed to determine compatible exposure parameters for
e-cigarette testing. Cell viability remained >90% in tissues exposed
to diluting air at vacuum rates of 5.0–50.0 mL/min for 3 h com-
pared with that in no-vacuum control tissues (Fig. 3B). After expo-
sure to diluting air or cigarette smoke at a diluting airﬂow rate of
1.0 L/min with vacuum rates of 5.0 mL/min or 25.0 mL/min for
3 h, cell viability was not affected in tissues exposed to smoke at
the lower vacuum rate (95.6%), but was reduced to 71.3% at the
higher vacuum rate relative to the untreated (incubator) control
tissues. Viability was not affected by exposure to diluting air rela-
tive to the untreated (incubator) control tissues at either vacuum
rate (Fig. 3C). The results demonstrate that a 25.0 mL/min vacuum
rate resulted in a statistically signiﬁcant decrease in viability
Fig. 2. EpiAirway™ tissue response following apical exposure, after 3 h exposure. (A) Heptyl butyrate and methyl stearate were shown to be non-irritants and butyl
methacrylate and heptanal to be irritants to the respiratory tract (Griesinger et al., 2009; OECD, 2013). Data show mean viability relative to vehicle controls and standard
deviation. (B) The vehicle control was olive oil. The viability of the positive control (0.1% Triton X-100) and the untreated (incubator) control was relative to the vehicle control
tissues. Boxplots show mean viability relative to vehicle controls, standard deviation, and range (n = 9).
Fig. 3. Effect of vacuum rates (mL/min) and exposure time on EpiAirway™ tissue cell viability. (A) Cell viability in control tissues (air controls n = 12 and positive controls
n = 27), relative to untreated (incubator) controls (n = 27) exposed to diluting air for 6 h. Boxplots show mean, standard deviation, and range. (B) Cell viability of tissues
exposed for 3 h to different vacuum rates (all n = 3) relative to no-vacuum control (n = 6). (C) Effect of cigarette smoke on tissue viability at vacuum rates of 5.0 and 25.0 mL/
min over 3 h relative to untreated (incubator) control. (⁄) show a signiﬁcant decrease (p = 0.004). (D) Effect of exposure to diluting airﬂow at 25.0 mL/min vacuum rate for up
to six hours exposure (n = 12 per exposure time) relative to untreated (incubator) control tissues. Data in B–D show mean and standard deviation.
1956 L. Neilson et al. / Toxicology in Vitro 29 (2015) 1952–1962following exposure to cigarette smoke compared with 5.0 mL/min
(p = 0.004). The length of exposure time using a 25 mL/min vac-
uum rate was also investigated. No change in cell viability was
seen with longer exposure relative to untreated (incubator) con-
trols (Fig. 3D).3.3. Deﬁning of puff numbers and demonstrating incremental doses
Due to the nature of machine smoking, the way in which the VC
01 operates, and given the potential product-to-product and
batch-to-batch variability in disposable e-cigarette performance,
puff number, smoking time to exhaustion, delivered deposited
mass and incremental delivered deposited mass over a 6 h
L. Neilson et al. / Toxicology in Vitro 29 (2015) 1952–1962 1957exposure period per product were independently investigated
(Fig. 4). Fig. 4A shows the puff number delivered per product and
the time to battery exhaustion (denoted by ﬂashing light as in nor-
mal use). Delivery of deposited mass was also investigated with
QCM technology. Finally, QCMs were used to assess incremental
deposits of aerosol mass over a 6 h exposure period. Puff number
and deposited mass differed little within and between products.
The average puff number for NJOY Bold and NJOY Menthol was
approximately 70 puffs per product, which equated to an average
of 35 min use before exhaustion. Mean deposited mass at the point
of exhaustion was approximately 75 lg/cm2 (Fig. 4B), and that for
aerosol over 6 h was approximately 3.5 times greater for both
e-cigarette products (140 lg/cm2) than for cigarettes (Fig. 4C).
These results enabled more appropriate experimental design. For
example, e-cigarette test products were matched for 60 puffs
(equal to 30 min per product) conﬁdently without fear of battery
exhaustion. The QCM results support that the technology is com-
patible with e-cigarette testing and demonstrates an incremental
increase in dose for up to 6 h.3.4. Cigarette smoke cytotoxicity
Cell viability of EpiAirway™ tissues exposed to diluting air ﬂow
remained unaffected at all exposure conditions relative to
untreated (incubator) controls (Fig. 5A). Tissue cell viability follow-
ing cigarette smoke exposure was reduced in a time-dependent
and dose-dependent manner from 100% to 12% viability after 6 h
of exposure relative to untreated (incubator) controls (Fig. 5B).
The ET50 value for cigarette smoke was 3.2 h (R2 = 0.97). The reduc-
tion in cell viability was approximately 20% per hr for the ﬁrst 5 h.
TEER results (expressed as a percentage of the pre-exposure value)
followed a similar pattern to the decrease in cell viability in tissues
exposed to cigarette smoke, except for a slight increase at 2 h, with
complete loss being seen by 5 h (Fig. 5B). Tissues exposed to dilut-
ing air showed only a moderate decrease in TEER, to approximately
60% of the pre-exposure value after 6 h of exposure, despite no loss
in cell viability (Fig. 5A).3.5. Electronic cigarette cytotoxicity
Unlike cigarettes, exposure of EpiAirway™ tissue to either vari-
ety of e-cigarette did not reduce tissue viability relative to
untreated (incubator) control tissues (Fig. 6A). As such an ET50
for e-cigarette aerosol could not be calculated. No statistical differ-
ence in viability was seen between NJOY Bold or NJOY Menthol and
diluting air controls. Greater variations between results were seen
for TEER (Fig. 6B). The highest TEER values were generally seen in
the diluting air control tissues, whereas those for NJOY Menthol
were the lowest. At 1 h all tissues had TEER of 76–92% of the
pre-exposure value and 38–59% at 6 h. Nevertheless, no statistical
difference in TEER values was seen between NJOY Bold or NJOY
Menthol compared with the diluting air controls. The loss in
TEER did not correspond with a reduction in cell viability, as was
seen for exposure to cigarette smoke.
A dose-dependent decrease in cell viability was seen following
incremental hourly exposures to cigarette smoke for up to 6 h,
resulting in reductions of around 90% at the highest dose (Fig. 7).
By contrast, the two e-cigarettes did not cause cytotoxic effects
under any of the test conditions, despite a much larger puff volume
and exposure frequency in the e-cigarette machine smoking
regime (Table 1), and cell viability did not differ between products.
Cell viability differed signiﬁcantly after exposure to cigarette
smoke and exposure to NJOY Bold or NJOY Menthol.4. Discussion
This study conﬁrms that a commercially available 3D, fully dif-
ferentiated tissue model of primary human tracheobronchial
epithelium can be used to test irritation from e-cigarette aerosols
at the air–liquid interface, with use of a MTT cytotoxicity endpoint.
EpiAirway™ tissues were apically assessed with known irritants.
Furthermore, the cytotoxic effects were compared between cigar-
ette smoke and e-cigarette aerosols. Exposure conditions were
thoroughly investigated alongside the VC 01, to optimise the air–
liquid interface model for in vitro testing. Table 2 shows a list of
all exposure parameters employed in this study and the rationale
behind their selection.4.1. Apical exposure
Since EpiAirway™ tissues are grown at the air–liquid interface,
the apical surface is exposed to the atmosphere and is amenable to
topical exposure. The ability of tissues to distinguish between
known respiratory tract irritants and non-irritants was conﬁrmed
with liquid preparations before aerosol exposure. Known irritants,
butyl methacrylate and heptanal, are classiﬁed as respiratory irri-
tants (H355) under Speciﬁc Target Organ Toxicity for single expo-
sure category 3 (UN, 2009; EC, 2008). Non-irritants, methyl
stearate and heptyl butyrate, have no classiﬁcation codes associ-
ated with irritation of the respiratory tract, skin, or eye. An irritant
effect was conﬁrmed if the test article caused a reduction of 50%
cell viability relative to negative controls (OECD, 2013) with a con-
centration dependent response. EpiAirway™ cultures correctly
predicted the toxic effects following treatment with known respi-
ratory tract irritants (butyl methacrylate and heptanal) and
non-irritants (methyl stearate and heptyl butyrate) for 3 h.
Variability in the cell viability across tissue replicates treated with
the non-irritants is generally recognised as an issue in 3D tissue
models. A sufﬁcient number of replicates (at least three) must,
therefore, be included (ECVAM, 2009, OECD, 2013) and a biologi-
cally relevant dose response should be established to conﬁrm the
presence of an irritant effect.4.2. Exposure parameters
Once the response of the EpiAirway™ tissue model to apical
exposures was conﬁrmed, the effects of vacuum rate and exposure
time were assessed to determine optimal exposure parameters for
e-cigarette testing (Table 2). No signiﬁcant decrease in viability
was seen in 3D tissue samples at vacuum ﬂow rates up to
50.0 mL/min for 3 h compared with no-vacuum controls. Given
this, a 25 mL/min vacuum rate was selected to increase dose with-
out over-stressing the cells. Previous studies that have assessed
monolayer cells with airﬂow delivered by vacuum demonstrated
no notable reduction in viability with vacuum rates of up to
5.0 mL/min for 1 h and 4 h (Kim et al., 2013; Li et al., 2014) and
8.3 mL/min/well for up to 2 h (Aufderheide et al., 2003). To support
the hypothesis that a higher vacuum ﬂow rate would result in a
higher dose of aerosol reaching the tissues, cigarette smoke was
tested in the system at two vacuum rates, 5.0 mL/min and
25.0 mL/min, for 3 h. Cell viability was signiﬁcantly reduced at
the higher vacuum rate (25 mL/min), when compared to the lower
ﬂow rate (5 mL/min), suggesting that increasing vacuum rate in
this system has an impact on dose delivery and that the
25 mL/min vacuum rate delivered more to the cell system than
the 5 mL/min vacuum rate. Furthermore, a 25 mL/min vacuum rate
was assessed over 6 h with ﬂowing air exposure, and control tis-
sues remained unaffected.
Fig. 4. Deﬁning of puff numbers and demonstrating incremental doses for biological exposure. (A) Puff number per e-cigarette until exhaustion (n = 7 each, four replicates per
occasion). (B) Deposited mass per e-cigarette until exhaustion (n = 7 each, four replicates per occasion). (C) Incremental dose increase observed for up to 6 h for cigarettes, and
e-cigarettes. Cigarettes smoked to 30.02.60, e-cigarettes smoked to 80.03.60 (60 puffs), n = 3, four replicates per occasion. Data shows mean and standard deviation.
Fig. 5. Exposure of EpiAirway™ tissues to diluting air (A) or cigarette smoke (B). Six tissue replicates were exposed per time point. Cell viability presented relative to
untreated (incubator) control tissues, and TEER is presented as a percentage of the pre-exposure value, showing mean and standard deviation.
1958 L. Neilson et al. / Toxicology in Vitro 29 (2015) 1952–1962Reference 3R4F cigarettes were smoked to the ISO smoking
regime (35 mL puff drawn over 2 s with 1 min interval) using
an 8 s exhaust and a bell-shaped smoking curve in accordance
with the standard ISO 3308:2012. E-Cigarettes were puffed to
an independent intense regime, deﬁned by a 80 mL puff drawn
over 3 s at 30 s intervals, using a square-wave pufﬁng proﬁle,
to actuate the electronic device. Due to the lack of any recog-
nised or standardised E-Cigarette pufﬁng regime, this study has
employed a more intensive regime with an 80 mL puff over 3 s
every 30 s compared to standard ISO or Health Canada Intense
regimes (Table 1).4.3. Puff number and incremental dose
Disposable e-cigarettes are potentially variable and it was
essential that a puff number was established for each e-cigarette
to minimise the risk of a lack of aerosol being provided to the tis-
sues during exposure. The puff number was set at 60 puffs per
product. QCM data conﬁrmed that aerosol was delivered consis-
tently, and conﬁrmed that incremental doses of e-cigarette aerosol
and cigarette smoke were reﬂected by deposited mass obtained
over a 6 h exposure period, supporting continued exposure, and
giving conﬁdence in exposure consistency.
Fig. 6. Exposure of EpiAirway™ tissues to e-cigarette aerosol or air diluting control. Three tissue replicates were exposed to each e-cigarette aerosol and six to diluting air per
time point. (A) Cell viability presented relative to untreated (incubator) control tissues. (B) TEER was presented as a percentage of the pre-exposure value. ⁄NJOY Bold vs.
control, p = 0.1902; NJOY Menthol vs control, p = 0.306. ⁄⁄NJOY Bold vs. control, p = 0.4887; NJOY Menthol vs control, p = 0.737. Data in A and B show mean and standard
deviation.
Fig. 7. Comparison of cytotoxicity after exposure to cigarette smoke and e-cigarette
aerosol. Six tissue replicates were exposed to cigarette smoke and three tissue
replicates were exposed to aerosol from each e-cigarette product per time-point.
Data presented relative to untreated (incubator) control tissues showing mean and
standard deviation. ⁄NJOY Bold vs. cigarette smoke, p = 0.0082; NJOY Menthol vs.
cigarette smoke, p = 0.0168.
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more than that deposited by cigarettes (Fig. 4C). Due to the nature
of machine smoking and the way in which the VC 01 operates,
e-cigarette performance was assessed by independently investi-
gating puff number, smoking time to exhaustion, delivered depos-
ited mass, and incremental delivered deposited mass over 6 h.
Investigating these parameters separately is important to ensure
appropriate experimental design, and especially because the
potential variability within and between e-cigarettes is unknown.
Data demonstrated that puff number and deposited mass varied
little in this study. This is an important ﬁnding, given that as the
e-cigarette battery fails, so does the consistency and performance
of the product and therefore the ability of the product to deliver
a consistent aerosol. To avoid any battery failing associated effects,
a cut-off of 60 puffs (30 min use), was implemented, which was 10
puffs (5 min) less than the recorded average for NJOY Bold and
NJOY Menthol.4.4. Cigarette smoke cytotoxicity
Exposure to cigarette smoke at a 1 L/min diluting airﬂow and
25 mL/min vacuum rate for up to 6 h resulted in a
time-dependent and dose-dependent reduction in cell viability to12% demonstrating the ability to induce and measure aerosol irri-
tancy utilising EpiAirway™ tissues and the VITROCELL VC 01
smoking robot. The cytotoxicity of cigarette smoke has been
reported in various studies at the air–liquid interface (Okuwa
et al., 2010; Weber et al., 2013; Li et al., 2014; Thorne et al.,
2014; Misra et al., 2014), and all have shown clear
dose-dependent reductions in cell viability with increasing smoke
concentrations.
TEER also showed a dose-dependent reduction over time in tis-
sue samples exposed to cigarette smoke, dropping signiﬁcantly to
approximately 30% of the pre-exposure value after 3 h and with
complete loss at 5 and 6 h. The loss of tight junctions integrity is
consistent with the levels of cytotoxicity observed at the 5–6 h
time points, i.e. complete loss of membrane integrity and cellular
death. TEER decreased moderately in tissues exposed to diluting
air (by approximately 60% of the pre-exposure value) after 6 h of
exposure, although no loss was seen in cell viability. This ﬁnding
might indicate early signs of tissue stress due to airﬂow across
the tissue surface. Exposure to cigarette smoke has been reported
to cause a loss in bronchial epithelium-barrier function as mea-
sured by TEER, which was concluded to be due to a regulated pro-
cess rather than owing to a cytotoxic response (Olivera et al.,
2007). Balharry et al., 2008 measured the TEER response as an indi-
cator of tissue stress in EpiAirway™ tissue samples apically
exposed to tobacco smoke components, and saw a biphasic
response, where TEER increased at low concentrations then stea-
dily decreased with increasing concentration. They concluded that
the TEER peak could act as an early indicator for toxic effects and
deterioration of the model. We saw similar pattern, with an
increase in TEER seen after 2 h of exposure to cigarette smoke com-
pared with after 1 h (increase to 90% from 75%) followed by a steep
reduction in TEER and cell viability.4.5. Electronic cigarette cytotoxicity
No reduction was seen in tissue cell viability and the results for
e-cigarette aerosol did not differ signiﬁcantly from the untreated
air controls, after 6 h of continuous exposure. The reductions seen
in TEER with exposure to e-cigarette aerosols were not statistically
different from those for the diluting air controls at 6 h, which
demonstrates no effect on tissues. The diluting air controls in the
cigarette smoke and e-cigarette experiments showed general
trends for a reduction of 20% in TEER values after 1 h and to 60%
after 6 h. One possible explanation for the observed reduction in
TEER values, could be that the ﬂowing air over the cells after 6 h,
Table 2
Study parameters and the rationale behind their selection.
Parameter Value Rationale Figure/Table/
Reference
Pufﬁng regime ISO for cigarettes;
independent regime for
e-cigarettes testing
ISO regime is a recognised standard for machine smoking of cigarettes; Limited data and no current
standards exist for e-cigarette testing and, therefore, a high puff volume and frequency were selected,
deﬁned as an 80 mL puff drawn over 3 s at 30 s intervals, and using a square-wave pufﬁng proﬁle
Table 1
Diluting airﬂow
(L/min)
1.0 L/min As the VC 01 has only one smoking position and associated dilution bar, diluting airﬂow was set and
dose was controlled with incremental increases in products;
1.0 L/min was selected as it is the highest smoke concentration achievable with consistent dose across
the module
Adamson
et al. (2014)
Vacuum ﬂow
rate (mL/min)
25 mL/min Comparison of vacuum rates on control tissues showed little effect on viability up to a 50 mL/min ﬂow
rate over a 3 h period. A 25 mL/min vacuum rate was selected to avoid over-stress to tissue samples,
and compared with a 5 mL/min vacuum rate, a greater cytotoxic response was seen with 25 mL/min.
Considering neither vacuum rate affected the control tissues under ﬂowing air conditions, it was
hypothesised that 25 mL/min delivers more vapour-phase components to the cell exposure interface
and, therefore, is a more intense exposure option
Fig. 3B/C
Exposure time
(h)
Up to 6 h With a 25 mL/min vacuum rate cells were exposed to ﬂowing sterile air for up to 6 h and
demonstrated no decrease in viability
Fig. 3D
Puff number (per
e-cigarette)
60 puffs/e-cigarette Analysis of the puff proﬁles of e-cigarettes and the exhaustion times identiﬁed a 30 min smoking
duration and a 60 puff limit is consistently achievable before the battery fails for the products tested
in this study
Fig. 4A
1960 L. Neilson et al. / Toxicology in Vitro 29 (2015) 1952–1962caused an element of dehydration to the tissues and as a result
effected TEER readings. However, as no reduction in cell viability
was seen in the tissues exposed to either the diluting air control
or the e-cigarette aerosol, it brings into question to what extent
TEER would be an indicator of tissue stress and whether the
TEER value could recover. This may suggest that although no
increase in cytotoxicity was observed at the 6 h time point, 6 h
exposure and a 25 mL/min vacuum ﬂow over the cells may be
the upper limit of exposure that these tissues are capable of.
There was no clear difference in effect, as measured by MTT,
between the different e-cigarettes tested, which shows that the
differences in the formulated e-liquids (nicotine levels and inclu-
sion of menthol) did not affect the potential irritancy of the aerosol.
This observation differs from that in a recent study reported by
Cervellati et al., 2014, in which a progressive loss in viability (mea-
sured by Trypan blue) over time was seen in lung alveolar cells
(A549) after 50 min exposure to e-cigarette aerosol containing ﬂa-
vours and nicotine. In contrast, e-cigarette aerosol void of ﬂavours
and nicotine had no effect on the viability of the cells. Nevertheless,
they concluded that e-cigarette aerosol was far less cytotoxic than
cigarette smoke. The observed differences between studies could
be a result of different cell systems being employed (3D vs. mono-
layer cultures) and/or a difference in the exposure set-up of these
experiments. 3D cell constructs are differentiated multi-layered,
organotypic structures, with deﬁned and functional cilia and
mucus secreting cells, and as such represent a more biologically
accurate system for exposure at the air–liquid interface, when
compared to the human situation. These 3D systems are however,
far different from a cell monolayer consisting of a single cell type,
usually of a carcinoma or transformed phenotype (BéruBé et al.,
2010). The response of a particular chemical or chemicals can differ
depending on the cell system employed. For example, Balharry
et al., 2008 noted that 3D cultures were more toxicologically resis-
tant to some tobacco smoke toxicants compared to common undif-
ferentiated cell lines. This observation was theorised to be a result
of the tissues robust in vivo like nature, consisting of interacting
cell types distributed through an organotypic-like structure, which
is far more representative of the human situation, compared to a
monolayer cell system (Balharry et al., 2008). These cellular
choices would also explain the differences reported from other api-
cal e-liquid (Bahl et al., 2012) and e-cigarette vapour extract stud-
ies (Farsalinos et al., 2013; Romagna et al., 2013). The lack of an
irritant effect in tissues exposed to e-cigarette aerosol shows a
clear contrast to the effects seen with exposure to cigarette smoke
(Fig. 7). In combination with the QCM data, which demonstratesthat e-cigarettes provided approximately 3.5 times more deposited
mass than cigarette smoke, the absence of an irritant effect is
reassuring.4.6. Study considerations
This study employed EpiAirway™ tissues derived from a single
individual donor and did not investigate donor-to-donor variabil-
ity. This is an important consideration, as donor variability, espe-
cially in differentiated 3D tissue models such as EpiAirway™ may
affect in vitro results. In order to assess the potential impact of
donor variability on this methodology, an additional multiple
donor study would need to be investigated.
In combination with a cytotoxicity end-point, cellular junction
integrity was assessed through transepithelial resistance (TEER).
TEERs can be employed as an early indication of in vitro cellular
stress and as a precursor to cytotoxicity. For a more mechanistic
based approach, additional end-points such as gene regulation
and cellular mediators could be employed. For example, cigarette
smoke and other airborne particulates have been shown to upreg-
ulate a series of factors linked to lung inﬂammation (chemokines
and cytokines), tissue remodelling, and mucin overproduction. In
addition pro-inﬂammatory cytokine interleukin-6 (IL-6), neu-
trophil chemoattractant interleukin-8 (IL-8), matrix
metalloprotease-1 (MMP-1) and growth-related oncogene-a
(GRO-a) have all been shown to be upregulated following smoke
and particle exposure (Seagrave et al., 2004; Auger et al., 2006;
Haswell et al., 2010; Newland et al., 2011). The application of such
analyses may support future in vitro testing scenarios and aid in aid
in the discrimination of e-cigarette aerosols.
Finally, differentiated EpiAirway™ tissues may lend themselves
to a more chronic or repeated exposure scenario, which would fur-
ther mimic human exposure. This study has only investigated an
acute continuous (6 h) exposure, but additional repeated exposure
method development coupled with mediator analysis as men-
tioned above may enable this preliminary technique to be utilised
to its fullest potential within an in vitro testing scenario, providing
the research questions are clearly deﬁned. In the case of this study,
the aimwas to develop an in vitro screeningmodel based on a com-
parable OECD test guideline 439 (OECD, 2013), using an aerosol
exposure system and differentiated human tracheal/bronchial
epithelium, to start to mimic human exposure. Current OECD
guidelines do not use repeated exposure or mediator analysis to
supplement biological data.
L. Neilson et al. / Toxicology in Vitro 29 (2015) 1952–1962 19615. Conclusion
The use of 3D organotypic cultures offers the unique opportu-
nity to investigate the direct toxicological responses in a system
exposed at the air–liquid interface in vitro. A combined system that
more closely mimics the in vivo human situation and therefore
allows more realistic data to be obtained and therefore more accu-
rate conclusions to be drawn on the resulting data.
This study demonstrates the applicability of physiologically rele-
vant EpiAirway™ tissue used in combination with a VITROCELL VC
01 exposure system for the assessment and comparison of cigarette
smoke and e-cigarette aerosol. Despite being tested with a more
intense pufﬁng regime, e-cigarette aerosol showed no acute cytotox-
icity in this study when compared with traditional 3R4F reference
cigarette smoke. Under the study conditions cigarette smoke demon-
stratedadose-dependent response that resulted innear-completecell
death after a 6 h exposure period. In contrast, e-cigarette aerosol
showed no decrease in tissue viability following a 6 h exposure,
despite appropriatepositive control responses. Furthermore, cytotox-
icity appears to be unaffected by different e-cigarette formulations as
tested in this study. Further studieswill need to be conducted to com-
parebetweendifferent commercially availableproducts, formats, and
formulations, but our data suggest that e-cigarette aerosols have sig-
niﬁcantly less impact than cigarette smoke over the duration of a 6 h
exposure in vitro using organotypic tissue constructs.
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